Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index (Q30558739)

24 June 2017

Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index (English)

1 reference

24 June 2017

0 references

Richard Pencek

1

1 reference

24 June 2017

Amy Blickensderfer

2

1 reference

24 June 2017

Yan Li

3

1 reference

24 June 2017

Steven C Brunell

4

1 reference

24 June 2017

Pamela W Anderson

5

1 reference

24 June 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

24 June 2017

Postgraduate Medicine

1 reference

24 June 2017

124

1 reference

24 June 2017

21-32

1 reference

24 June 2017

4

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

24 June 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

The relationship between glycemic control and falls in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2567

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.07.2567

1 reference

24 June 2017

1 reference